Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
MediWound
MDWD
MediWound
Regulatory Delays Will Restrict Growth Though Future Promise Emerges
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
12 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$25.00
29.6% undervalued
intrinsic discount
16 Aug
US$17.61
Loading
1Y
-5.1%
7D
-2.7%
Author's Valuation
US$25.0
29.6% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$25.0
29.6% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-28m
52m
2014
2017
2020
2023
2025
2026
2028
Revenue US$51.8m
Earnings US$12.0m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
36.06%
Pharma revenue growth rate
0.57%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.34%
Calculation
US$12.02m
Earnings '28
x
45.53x
PE Ratio '28
=
US$547.17m
Market Cap '28
US$547.17m
Market Cap '28
/
17.21m
No. shares '28
=
US$31.79
Share Price '28
US$31.79
Share Price '28
Discounted to 2025 @ 8.34% p.a.
=
US$25.00
Fair Value '25
